These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31569615)

  • 1. In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.
    Papazoglou ED; Jagirdar RM; Kouliou OA; Pitaraki E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Deoxy-glucose Enhances the Effect of Cisplatin and Pemetrexed in Reducing Malignant Pleural Mesothelioma Cell Proliferation But Not Spheroid Growth.
    Gerogianni I; Pitaraki E; Jagirdar RM; Kouliou O; Giannakou L; Giannopoulos S; Papazoglou E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Anticancer Res; 2019 Jul; 39(7):3809-3814. PubMed ID: 31262908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of pharmacological primary cilium disturbance in the context of in vitro 2D and 3D malignant pleura mesothelioma.
    Jagirdar RM; Pitaraki E; Kotsiou OS; Rouka E; Sinis SI; Varsamas C; Marnas P; Stergiopoulou E; Giannou A; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Biochem Biophys Res Commun; 2023 Apr; 654():128-135. PubMed ID: 36907140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of AQP1 on cell adhesion, migration, and tumor sphere formation in malignant pleural mesothelioma is substratum- and histological-type dependent.
    Jagirdar RM; Apostolidou E; Molyvdas PA; Gourgoulianis KI; Hatzoglou C; Zarogiannis SG
    Am J Physiol Lung Cell Mol Physiol; 2016 Mar; 310(6):L489-95. PubMed ID: 26773069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
    Onen HI; Yilmaz A; Alp E; Celik A; Demiroz SM; Konac E; Kurul IC; Menevse ES
    Hum Exp Toxicol; 2015 Feb; 34(2):117-26. PubMed ID: 25028262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell and extracellular matrix interaction models in benign mesothelial and malignant pleural mesothelioma cells in 2D and 3D in-vitro.
    Jagirdar RM; Papazoglou ED; Pitaraki E; Kouliou OA; Rouka E; Giannakou L; Giannopoulos S; Sinis SI; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Clin Exp Pharmacol Physiol; 2021 Apr; 48(4):543-552. PubMed ID: 33336399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benign Pleural Mesothelial Cells Have Higher Osmotic Water Permeability than Malignant Pleural Mesothelioma Cells and Differentially Respond to Hyperosmolality.
    Katkova LE; Baturina GS; Bondar AA; Jagirdar RM; Hatzoglou C; Gourgoulianis KI; Solenov EI; Zarogiannis SG
    Cell Physiol Biochem; 2019; 52(4):869-878. PubMed ID: 30958661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.
    Mumblat H; Martinez-Conde A; Braten O; Munster M; Dor-On E; Schneiderman RS; Porat Y; Voloshin T; Davidi S; Blatt R; Shteingauz A; Tempel-Brami C; Zeevi E; Lajterer C; Shmueli Y; Danilov S; Haber A; Giladi M; Weinberg U; Kinzel A; Palti Y
    Lung Cancer; 2021 Oct; 160():99-110. PubMed ID: 34482104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
    Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
    Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in expression of mesothelial BBS genes in 2D and 3D after lithium chloride and ammonium sulphate induction of primary cilium disturbance: a pilot study.
    Rouka E; Jagirdar RM; Sarrigeorgiou I; Pitaraki E; Sinis SI; Varsamas C; Papazoglou ED; Kotsiou OS; Lymberi P; Giannou A; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
    Pharmacol Rep; 2023 Oct; 75(5):1230-1239. PubMed ID: 37542187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
    Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T
    Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma.
    Cioce M; Canino C; Pass H; Blandino G; Strano S; Fazio VM
    J Exp Clin Cancer Res; 2021 Nov; 40(1):344. PubMed ID: 34727953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.
    Hayashi H; Okamoto I; Ichikawa Y; Miyazaki M; Yoshioka H; Kunimasa K; Nakagawa K
    Int J Clin Oncol; 2010 Oct; 15(5):497-9. PubMed ID: 20224880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
    Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
    Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
    Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
    Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
    Boons CC; VAN Tulder MW; Burgers JA; Beckeringh JJ; Wagner C; Hugtenburg JG
    Anticancer Res; 2013 Sep; 33(9):3553-61. PubMed ID: 24023280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed in malignant pleural mesothelioma.
    Gatzemeier U
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 8):26-31. PubMed ID: 15655933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
    Scagliotti GV; Gaafar R; Nowak AK; Reck M; Tsao AS; van Meerbeeck J; Vogelzang NJ; Nakano T; von Wangenheim U; Velema D; Morsli N; Popat S
    Clin Lung Cancer; 2017 Sep; 18(5):589-593. PubMed ID: 28690011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways.
    Sun R; Tanino R; Tong X; Haque EF; Amano Y; Isobe T; Tsubata Y
    Transl Lung Cancer Res; 2022 Apr; 11(4):543-559. PubMed ID: 35529797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.